Taiwan
· Delayed Price · Currency is TWD Maxigen Biotech Statistics
Total Valuation
Maxigen Biotech has a market cap or net worth of TWD 3.95 billion. The enterprise value is 3.24 billion.
| Market Cap | 3.95B |
| Enterprise Value | 3.24B |
Important Dates
The next estimated earnings date is Wednesday, July 30, 2025.
| Earnings Date | Jul 30, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Maxigen Biotech has 89.68 million shares outstanding. The number of shares has increased by 0.96% in one year.
| Current Share Class | 89.68M |
| Shares Outstanding | 89.68M |
| Shares Change (YoY) | +0.96% |
| Shares Change (QoQ) | +0.24% |
| Owned by Insiders (%) | 0.78% |
| Owned by Institutions (%) | 2.00% |
| Float | 45.29M |
Valuation Ratios
The trailing PE ratio is 19.00.
| PE Ratio | 19.00 |
| Forward PE | n/a |
| PS Ratio | 5.40 |
| PB Ratio | 2.67 |
| P/TBV Ratio | 2.67 |
| P/FCF Ratio | 13.73 |
| P/OCF Ratio | 12.39 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.85, with an EV/FCF ratio of 11.28.
| EV / Earnings | 15.53 |
| EV / Sales | 4.44 |
| EV / EBITDA | 13.85 |
| EV / EBIT | 15.70 |
| EV / FCF | 11.28 |
Financial Position
The company has a current ratio of 4.18
| Current Ratio | 4.18 |
| Quick Ratio | 3.76 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 14.75% and return on invested capital (ROIC) is 9.12%.
| Return on Equity (ROE) | 14.75% |
| Return on Assets (ROA) | 8.11% |
| Return on Invested Capital (ROIC) | 9.12% |
| Return on Capital Employed (ROCE) | 13.90% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.46 |
| Inventory Turnover | 2.76 |
Taxes
In the past 12 months, Maxigen Biotech has paid 37.25 million in taxes.
| Income Tax | 37.25M |
| Effective Tax Rate | 15.14% |
Stock Price Statistics
The stock price has decreased by -6.38% in the last 52 weeks. The beta is 0.17, so Maxigen Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.17 |
| 52-Week Price Change | -6.38% |
| 50-Day Moving Average | 43.52 |
| 200-Day Moving Average | 45.12 |
| Relative Strength Index (RSI) | 53.67 |
| Average Volume (20 Days) | 60,526 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Maxigen Biotech had revenue of TWD 730.77 million and earned 208.84 million in profits. Earnings per share was 2.32.
| Revenue | 730.77M |
| Gross Profit | 520.82M |
| Operating Income | 206.60M |
| Pretax Income | 246.09M |
| Net Income | 208.84M |
| EBITDA | 234.10M |
| EBIT | 206.60M |
| Earnings Per Share (EPS) | 2.32 |
Balance Sheet
The company has 702.88 million in cash and n/a in debt, giving a net cash position of 702.88 million or 7.84 per share.
| Cash & Cash Equivalents | 702.88M |
| Total Debt | n/a |
| Net Cash | 702.88M |
| Net Cash Per Share | 7.84 |
| Equity (Book Value) | 1.48B |
| Book Value Per Share | 16.48 |
| Working Capital | 668.21M |
Cash Flow
In the last 12 months, operating cash flow was 318.52 million and capital expenditures -31.07 million, giving a free cash flow of 287.45 million.
| Operating Cash Flow | 318.52M |
| Capital Expenditures | -31.07M |
| Free Cash Flow | 287.45M |
| FCF Per Share | 3.21 |
Margins
Gross margin is 71.27%, with operating and profit margins of 28.27% and 28.58%.
| Gross Margin | 71.27% |
| Operating Margin | 28.27% |
| Pretax Margin | 33.67% |
| Profit Margin | 28.58% |
| EBITDA Margin | 32.03% |
| EBIT Margin | 28.27% |
| FCF Margin | 39.34% |
Dividends & Yields
This stock pays an annual dividend of 0.83, which amounts to a dividend yield of 1.89%.
| Dividend Per Share | 0.83 |
| Dividend Yield | 1.89% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | 42.60% |
| Buyback Yield | -0.96% |
| Shareholder Yield | 0.95% |
| Earnings Yield | 5.29% |
| FCF Yield | 7.28% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 7, 2023. It was a forward split with a ratio of 1.05.
| Last Split Date | Sep 7, 2023 |
| Split Type | Forward |
| Split Ratio | 1.05 |
Scores
Maxigen Biotech has an Altman Z-Score of 12.77 and a Piotroski F-Score of 6.
| Altman Z-Score | 12.77 |
| Piotroski F-Score | 6 |